Artivion, Inc. (NYSE:AORT) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Artivion, Inc. (NYSE:AORT) by 25.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,430 shares of the company’s stock after acquiring an additional 2,108 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Artivion were worth $186,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Exchange Traded Concepts LLC bought a new stake in Artivion in the fourth quarter worth approximately $916,000. Algert Global LLC acquired a new position in Artivion during the third quarter worth $566,000. GSA Capital Partners LLP raised its holdings in Artivion by 187.5% during the third quarter. GSA Capital Partners LLP now owns 82,449 shares of the company’s stock valued at $1,250,000 after buying an additional 53,773 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Artivion in the third quarter worth about $1,034,000. Finally, First Eagle Investment Management LLC boosted its stake in shares of Artivion by 37.3% during the 3rd quarter. First Eagle Investment Management LLC now owns 526,528 shares of the company’s stock worth $7,982,000 after acquiring an additional 143,146 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Trading Up 13.2 %

Artivion stock opened at $23.85 on Wednesday. The business’s 50-day simple moving average is $20.48 and its 200-day simple moving average is $18.14. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $25.51. The firm has a market capitalization of $982.62 million, a PE ratio of -31.80 and a beta of 1.66. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.43 and a current ratio of 4.85.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.02 by $0.04. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. The company had revenue of $97.43 million for the quarter, compared to the consensus estimate of $92.30 million. During the same period in the previous year, the business posted $0.02 EPS. Equities research analysts forecast that Artivion, Inc. will post 0.26 earnings per share for the current year.

Insider Transactions at Artivion

In other news, VP Rochelle L. Maney sold 2,315 shares of Artivion stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.27, for a total transaction of $46,925.05. Following the sale, the vice president now owns 39,197 shares of the company’s stock, valued at approximately $794,523.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Artivion news, VP Rochelle L. Maney sold 2,315 shares of Artivion stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.27, for a total transaction of $46,925.05. Following the sale, the vice president now directly owns 39,197 shares of the company’s stock, valued at $794,523.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Amy Horton sold 1,695 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total value of $31,967.70. Following the transaction, the chief accounting officer now owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 149,952 shares of company stock worth $2,891,627. 8.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AORT. Stifel Nicolaus boosted their target price on Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC boosted their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.